Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer

Breast Cancer

Volumn 22, Issue 5, 2015, Pages 520-528

  Hisamatsu, Yuichi ^a   Tokunaga, Eriko ^a   Yamashita, Nami ^a   Akiyoshi, Sayuri ^a   Okada, Satoko ^a   Nakashima, Yuichiro ^a   Taketani, Kenji ^a   Aishima, Shinichi ^a   Oda, Yoshinao ^a   Morita, Masaru ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Adjuvant therapy; Breast cancer; FOXA1; GATA 3; HR positive HER2 negative

Indexed keywords

ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FOXA1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; FEMALE; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN TISSUE; JAPANESE (PEOPLE); LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GATA3 TRANSCRIPTION FACTOR; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 84940954066     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-013-0515-x     Document Type: Article

References (26)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.
3. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.
4. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168–76.
5. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.
6. Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7:340–7.
7. Badve S, Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol. 2009;62:6–12.
8. Lim KC, Lakshmanan G, Crawford SE, Gu Y, Grosveld F, Engel JD. GATA3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat Genet. 2000;25:209–12.
9. Kaufman CK, Zhou P, Pasolli HA, et al. GATA-3: an unexpected regulator of cell lineage determination in skin. Genes Dev. 2003;17:2108–22.
10. Ting CN, Olson MC, Barton KP, Leiden JM. Transcription factor GATA-3 is required for development of the T-cell lineage. Nature. 1996;384:474–8.
11. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006;127:1041–55.
12. Asselin-Labat ML, Sutherland KD, Barker H, et al. GATA-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 2007;9:201–9.
13. Mehra R, Varambally S, Ding L, et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005;65:11259–64.
14. Carlsson P, Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. Dev Biol. 2002;250:1–23.
15. Kaestner KH. The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism. Trends Endocrinol Metab. 2000;11:281–5.
16. Carroll JS, Brown M. Estrogen receptor target gene: an evolving concept. Mol Endocrinol. 2006;20:1707–14.
17. Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V. From the Cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA. 2005;102:11651–6.
18. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011;43:27–33.
19. Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer–correlation with luminal subtype A and survival. Clin Cancer Res. 2007;13:4415–21.
20. Ijichi N, Shigekawa T, Ikeda K, et al. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Hormon Cancer. 2012;3:147–59.
21. Mehta RJ, Jain RK, Leung S, et al. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat. 2012;131:881–90.
22. Hisamatsu Y, Tokunaga E, Yamashita N, et al. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012;19:1145–52.
23. Hoch RV, Thompson DA, Baker RJ, Weigel RJ. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer. 1999;84:122–8.
24. Parikh P, Palazzo JP, Rose LJ, Daskalakis C, Weigel RJ. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg. 2005;200:705–10.
25. Ademuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S. Expression of forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol. 2010;23:270–5.
26. Bernardo GM, Lozada KL, Miedler JD, et al. FOXA1 is an essential determinant of ERα expression and mammary ductal morphogenesis. Development. 2010;137:2045–54.